Abstract:Introduction: We assessed chronic liver disease (CLD)-related mortality in the U.S. using death data (2011-2021) obtained from National Vital Statistics System (NVSS). The average annual percentage change (AAPC) from the models selected by Joinpoint regression analysis over the pre-pandemic (2011-2019) and the 2019-2021 were reported because non-linear trend in death rates were observed over the 2011-2021. Liver-specific death was defined as an underlying cause of death and Chronic liver disease (CLD)-related death was defined as any cause of death. During the pre-pandemic, age-standardized HCC- and cirrhosis-specific death rates were annually increased by AAPC = +1.18% (95% confidence interval, 0.34% to 2.03%) and AAPC = +1.95% (1.56% to 2.35%). In contrast, during the 2019-2021, the AAPC in age-standardized cirrhosis-specific death rate (per 100,000) accelerated by up to AAPC +11.25% (15.23 in 2019 to 18.86 in 2021) whereas that in age-standardized HCC-specific death rate slowed to -0.39 (-1.32% to 0.54%) (3.86 in 2019 to 3.84 in 2021). Compared to HCC-specific deaths, cirrhosis-specific deaths were more likely to be non-Hispanic white (72.4% vs. 62.0%) and non-Hispanic American Indian and Alaska native (AIAN) (2.2% vs. 1.1%) and have NAFLD (45.3% vs. 12.5%) and ALD (27.6% vs. 22.0%). During the 2019-2021, the age-standardized HCV- and HBV-related death rate stabilized, whereas the age-standardized NAFLD- and ALD-related deaths rate increased to 20.16 in 2021 (AAPC = +12.13% [7.76% to 16.68%]) and to 14.95 in 2021 (AAPC = +18.30% [13.76% to 23.03%]), which were in contrast to much smaller incremental increases during the pre-pandemic (AAPC = +1.82% [1.29% to 2.35%] and AAPC = +4.54% [3.97% to 5.11%]), respectively). The most pronounced rise in the age-standardized NAFLD-related death rates during the pandemic was observed among AIAN (AAPC = +25.38%), followed by non-Hispanic White female (AAPC = +14.28%), whereas the age-standardized ALD-related death rates during the pandemic were highest among AIAN (AAPC = +40.65%), followed by non-Hispanic Black female (AAPC = +26.79%). Conclusions: COVID-19 pandemic had a major negative impact on cirrhosis-specific and CLD-related mortality in the U.S. with significant racial and gender disparities.

Impact of the COVID-19 Pandemic on Liver Disease-Related Mortality Rates in the United States.

Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States' National Vital Statistics System

Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States

Trends of Cirrhosis-related Mortality in the USA During the COVID-19 Pandemic

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States

A Meta-Analysis of the Impact of COVID-19 on Liver Dysfunction.

Racial and Ethnic Disparities in Years of Potential Life Loss among Patients with Cirrhosis During the COVID-19 Pandemic in the United States.

Excess Deaths of Gastrointestinal, Liver, and Pancreatic Diseases During the COVID-19 Pandemic in the United States.

Higher-Than-Expected Burden of Alcohol-Related Liver Diseases During COVID-19 Pandemic in the USA, with a Tapering Trend

Excess of Heart Failure-Related Deaths During the 2020 COVID-19 Pandemic in Unites States

Abnormal liver function on admission predicts severe outcomes in COVID-19 patients: a multicenter study (Preprint)

The Burden of Liver Cirrhosis and Underlying Etiologies: Results from the Global Burden of Disease Study 2019

Dynamic Changes in Liver Function Tests and Their Correlation with Illness Severity and Mortality in Patients with COVID-19: A Retrospective Cohort Study

Risk of Mortality among Patients with Alcohol-Associated Hepatitis in the US from 2007 to 2021

Association Between Non-Alcoholic Fatty Liver Disease with the Susceptibility and Outcome of COVID-19: A Retrospective Study.

Liver Injury in Patients with COVID-19: A Retrospective Study

Epidemiology of Alcohol-Associated Liver Disease Including Increasing Burden in Young Adults and Females Especially Since Covid-19 Pandemic

Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States

Estimating Global Prevalence, Incidence, and Outcomes of Non-Alcoholic Fatty Liver Disease from 2000 to 2021: Systematic Review and Meta-Analysis

Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China

Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States